{"id":"ct-l03","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Infections (including serious infections)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4297274","moleculeType":"Small molecule","molecularWeight":"533.80"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CT-L03 is a monoclonal antibody that binds to and neutralizes TNF-α, a key pro-inflammatory cytokine. By inhibiting TNF-α signaling, it reduces inflammatory responses in autoimmune and inflammatory conditions. As a biosimilar, it is designed to have comparable efficacy and safety to the reference biologic adalimumab.","oneSentence":"CT-L03 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:03.372Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Psoriasis"}]},"trialDetails":[{"nctId":"NCT07158346","phase":"PHASE1","title":"Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of CT-L03 in Healthy Volunteers","status":"COMPLETED","sponsor":"Celltrion","startDate":"2025-08-18","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":49},{"nctId":"NCT06571591","phase":"PHASE3","title":"Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celltrion","startDate":"2024-08-27","conditions":"T2DM","enrollment":582}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CT-L03","genericName":"CT-L03","companyName":"Celltrion","companyId":"celltrion","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CT-L03 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}